A phase 2, multi-center, open-label, dose-finding trial to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of OPC-41061 in patients with chronic renal failure undergoing hemodialysis or hemodiafiltratio

Phase 2

• Conditions: Patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration

• Registration Number: JPRN-jRCT2080222101
• Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-06-07
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1)Patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration three times a week
2)Subjects between the ages of 20 and 80, inclusive (at time of informed consent)
3)Subjects who are inpatients or who can be admitted to the trial site for the duration of the trial period
4)Subjects who, together with their partner, are able to practice one of the specified contraceptive methods until 4 weeks after the final trial drug administration
5)Patients who are capable of providing written informed consent themselves before any trial-related procedures are performed

Exclusion Criteria

1)Subjects with a complication of urinary impairment due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
2)Subject with daily urine volume less than 500 mL
3)Subject with Cardiac function of NYHA class 4
4)Subjects with serious ischemic heart disease, who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
5)Subjects with serious arrhythmia, who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
6)Subjects who are concomitantly undergoing peritoneal dialysis
7)Subjects with ascites due to cirrhosis or cancer, requring medical treatments
8)Subjects with any of the following medical histories:
- History of cerebrovascular disorder or coronary artery disease within 4 weeks prior to informed consent
- History of hypersensitivity or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride
9)Subjects with any of the following abnormal laboratory values:
- Hemoglobin lower than 8.0 g/dL, total bilirubin higher than 3.0 mg/dL, ALT (GPT) or AST (GOT) 2 times the upper limit of the reference range of the trial site, serum sodium higher than the upper limit of the reference range of the trial site, serum sodium lower than 125mEq/L
10)Subjects with serum potassium higher than 6.0mEq/L and abnormal findings inappropriate for inclusion in the trial are observed by 12-lead ECG
11)Subjects who are unable to sense thirst or who have difficulty with fluid or food intake
12)Subjects who have participated in any other clinical trial or post-marketing clinical studies within 4 weeks prior to informed consent
13)Female subjects who are pregnant, possibly pregnant, or nursing, or who plan to become pregnant during the trial period
14)Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
daily urine volume<br>Change and percent change from baseline

Secondary Outcome Measures

Name	Time	Method
Total fluid removal per week by dialyses<br>Change and percent change from baseline